Viscoelastic Testing in Complex Critical Bleeding

Abstract

Complex critical bleeding occurs when hemorrhage is accompanied by trauma, major surgery, obstetric complications, cardiac procedures, liver disease, anticoagulant exposure, or profound physiological derangement. Conventional laboratory tests such as prothrombin time, activated partial thromboplastin time, fibrinogen concentration, and platelet count remain clinically useful, but they provide incomplete and delayed information about the dynamic interaction among clot initiation, clot strength, fibrin polymerization, platelet contribution, and fibrinolysis. Viscoelastic testing, including thromboelastography and rotational thromboelastometry, evaluates whole-blood coagulation in real time and can support targeted hemostatic therapy. Its greatest value is observed when bleeding is rapid, multifactorial, and changing over time. Protocolized use may reduce unnecessary transfusion, identify hypofibrinogenemia or hyperfibrinolysis, and improve coordination between laboratory findings and bedside treatment. However, test interpretation requires expertise, quality assurance, validated reference ranges, and integration with clinical assessment. Evidence is strongest in trauma, cardiac surgery, liver transplantation, and selected obstetric and perioperative settings, while outcome benefits remain variable across institutions. This review summarizes the biological basis, clinical applications, limitations, and evolving role of viscoelastic testing in complex critical bleeding.

Introduction

Critical bleeding is a time-dependent syndrome in which blood loss, impaired coagulation, shock, and tissue hypoperfusion reinforce one another. Management requires rapid control of the bleeding source, restoration of circulating volume, correction of physiological abnormalities, and rational replacement of hemostatic components. In many patients, coagulation defects are not static. A patient may progress from early hypercoagulability to dilutional coagulopathy, hypofibrinogenemia, platelet dysfunction, or excessive fibrinolysis within a short period. Conventional plasma-based assays generally measure isolated portions of coagulation under artificial conditions and often take longer to report than clinically acceptable during uncontrolled hemorrhage.

Viscoelastic testing provides a functional assessment of clot formation and dissolution using whole blood. The technology measures the evolution of clot amplitude or elasticity from initial fibrin formation through maximum clot strength and subsequent lysis. Results can be available at the bedside or in a near-patient laboratory, allowing treatment decisions to be linked to the current hemostatic state. The principal platforms are thromboelastography and rotational thromboelastometry, with several assay configurations designed to isolate the effects of fibrinogen, platelets, heparin, or fibrinolysis. These tests are not replacements for clinical judgment or standard laboratory testing; rather, they are complementary tools for individualized resuscitation.

Epidemiology / Disease Burden

Major hemorrhage is a leading cause of preventable death after severe trauma and remains a major contributor to mortality in cardiac surgery, liver transplantation, ruptured vascular disease, gastrointestinal bleeding, postpartum hemorrhage, and complex oncological operations. The burden extends beyond mortality. Large-volume transfusion is associated with hypothermia, metabolic abnormalities, transfusion reactions, acute respiratory complications, infection risk, organ dysfunction, and prolonged intensive care. Inappropriate administration of plasma or prothrombin complex concentrates may also expose patients to thromboembolic complications.

The frequency and pattern of coagulopathy vary by clinical setting. Trauma-associated coagulopathy may be present before substantial fluid administration and can include impaired clot initiation, reduced clot strength, and accelerated fibrinolysis. Cardiopulmonary bypass introduces hemodilution, platelet dysfunction, residual heparin effects, and consumption of coagulation factors. Advanced liver disease produces a rebalanced but fragile hemostatic system in which standard tests may suggest hypocoagulation despite preserved or even increased thrombin-generating capacity. Obstetric hemorrhage can evolve rapidly from fibrinogen depletion to disseminated intravascular coagulation. These differences explain why locally validated algorithms are necessary.

Pathophysiology

Effective hemostasis depends on coordinated platelet adhesion and activation, thrombin generation, fibrin formation, cross-linking, clot contraction, and controlled fibrinolysis. Severe bleeding disrupts this system through tissue injury, shock, acidosis, hypothermia, endothelial activation, inflammation, dilution, and consumption. Hypoperfusion may increase activated protein C generation and impair thrombin formation, while tissue injury can release mediators that promote fibrinolysis. Fibrinogen is often the first coagulation substrate to reach critically low functional levels during massive hemorrhage because of consumption, dilution, and degradation.

Viscoelastic assays capture several of these processes simultaneously. The reaction time or clotting time reflects the delay before initial clot formation and may be prolonged by deficient coagulation factors, anticoagulant drugs, or heparin. The clot formation time and alpha angle describe the rate of clot development. Maximum clot firmness or maximum amplitude reflects the combined contribution of fibrin and platelets. Fibrin-specific assays estimate the fibrin component of clot strength, while the difference between total and fibrin-based clot strength can provide an indirect estimate of platelet contribution. Lysis indices and maximum lysis identify excessive fibrinolysis, although interpretation must account for assay conditions and timing.

Risk Factors

Risk factors for complex coagulopathy include severe tissue injury, traumatic brain injury, shock, prolonged hypotension, hypothermia, acidosis, low ionized calcium, large-volume crystalloid administration, delayed hemorrhage control, and prehospital or hospital transfusion. Medication-related risks include warfarin, direct oral anticoagulants, heparins, antiplatelet agents, and thrombolytic therapy. Liver failure, renal dysfunction, sepsis, disseminated intravascular coagulation, malignancy, and pre-existing thrombocytopenia further complicate interpretation and treatment.

Procedural factors are also important. Cardiopulmonary bypass, extracorporeal membrane oxygenation, ventricular assist devices, and mechanical circulatory support can produce altered platelet function, acquired von Willebrand factor abnormalities, and anticoagulant effects. In obstetric patients, placental abruption, amniotic fluid embolism, retained products of conception, and severe preeclampsia increase the likelihood of rapidly progressive consumptive coagulopathy. A prior history of bleeding does not necessarily predict the current mechanism, so testing should be interpreted in the context of the active clinical syndrome.

Clinical Features

Clinical manifestations range from visible surgical or traumatic hemorrhage to diffuse oozing from mucosal surfaces, vascular access sites, drains, and operative fields. Persistent shock despite fluid and blood replacement may indicate ongoing bleeding, inadequate source control, or severe hemostatic failure. Microvascular bleeding can coexist with apparently moderate blood loss when clot formation is impaired. Conversely, brisk bleeding from a large arterial or venous source may occur despite relatively preserved coagulation and will not be corrected by hemostatic products alone.

Additional indicators include falling hemoglobin, increasing transfusion requirements, worsening metabolic acidosis, rising lactate, hypothermia, ionized hypocalcemia, reduced platelet count, and declining fibrinogen. Clinical examination should assess perfusion, mental status, skin temperature, urine output, surgical field characteristics, and evidence of thrombotic complications. Viscoelastic results should therefore be viewed as part of a repeated clinical assessment rather than as an isolated trigger for treatment.

Diagnosis

Diagnosis begins with recognition of active or anticipated critical bleeding and simultaneous evaluation of the bleeding source and physiological reserve. Standard investigations commonly include complete blood count, fibrinogen, prothrombin time, activated partial thromboplastin time, blood gas analysis, lactate, electrolytes, ionized calcium, renal function, and medication history. These tests remain essential for trend assessment, diagnosis of specific disorders, and confirmation of treatment effects.

Viscoelastic testing is most informative when performed at baseline and repeated after major interventions or when the clinical picture changes. A prolonged clotting time may support plasma or factor replacement when factor deficiency is clinically relevant, whereas low fibrin-based clot amplitude supports fibrinogen replacement. Reduced overall clot strength with preserved fibrin contribution may suggest platelet-related impairment, although platelet count, antiplatelet exposure, and the clinical context must be considered. Excessive lysis may support antifibrinolytic therapy when hyperfibrinolysis is credible. Point-of-care testing reduces the delay between sample acquisition and treatment, but preanalytic errors, citrate handling, temperature, hemodilution, and device-specific reference ranges can substantially affect results.

Treatment & Management

Management requires simultaneous hemorrhage control and structured resuscitation. Surgical, endovascular, obstetric, or endoscopic intervention should not be delayed while waiting for laboratory results. A major hemorrhage protocol should ensure rapid access to red cells, plasma, platelets, fibrinogen replacement, calcium, warming devices, and appropriate pharmacological agents. Viscoelastic results can then guide transition from empiric component administration to targeted therapy.

Fibrinogen replacement may be provided with cryoprecipitate or fibrinogen concentrate, depending on local availability and institutional policy. Plasma or specific factor concentrates may be considered when delayed clot initiation reflects factor deficiency, although the risk of thrombosis and the underlying diagnosis must be evaluated. Platelet transfusion is generally considered when platelet number or function is inadequate in the setting of active bleeding, particularly during neurosurgery, cardiac surgery, or severe trauma. Tranexamic acid is beneficial in selected trauma and postpartum hemorrhage pathways when given early and when contraindications are absent; it should not be used indiscriminately in patients with suspected pathological hypercoagulability or established contraindications.

Supportive correction is fundamental. Hypothermia impairs enzymatic reactions and platelet activity, acidosis reduces coagulation efficiency, and hypocalcemia limits several calcium-dependent steps in coagulation. Reducing unnecessary crystalloid, maintaining adequate perfusion, correcting severe anemia according to clinical context, and reassessing after each intervention are central to effective care. Viscoelastic-guided algorithms may reduce exposure to plasma and platelets, but they do not eliminate the need for blood component therapy when losses are substantial.

Recent Advances / Emerging Therapies

Recent developments include smaller cartridge-based systems, improved automation, faster analysis, and integration of viscoelastic results into electronic transfusion and emergency response pathways. Some institutions are evaluating combined algorithms that incorporate viscoelastic data with platelet function testing, fibrinogen measurement, anticoagulant-specific assays, and clinical prediction tools. These approaches may improve discrimination between low clot strength caused by fibrinogen deficiency, platelet dysfunction, or factor abnormalities.

Research is also examining the role of viscoelastic testing in direct oral anticoagulant exposure, extracorporeal support, sepsis, liver transplantation, and personalized perioperative blood conservation. Concentrated factor products, pathogen-reduced components, lyophilized plasma, and novel reversal agents may expand treatment options, but their appropriate use requires careful attention to cost, thrombotic risk, availability, and patient selection. Artificial intelligence and automated decision support may eventually assist interpretation, although prospective validation and transparent clinical governance are essential before routine adoption.

Guideline Recommendations

Current trauma, cardiac surgery, perioperative, and obstetric guidance generally supports early activation of a major hemorrhage pathway, rapid source control, prevention of hypothermia and hypocalcemia, and repeated assessment of coagulation status. Where validated local protocols exist, viscoelastic testing can be used to guide targeted replacement of fibrinogen, platelets, plasma, and selected coagulation factors. Guidelines emphasize that antifibrinolytic therapy is time-sensitive in appropriate trauma and obstetric cases and that treatment should be based on the clinical syndrome rather than an isolated laboratory abnormality.

Professional recommendations also stress that viscoelastic testing should be performed by trained personnel, with documented quality control, defined turnaround targets, and algorithms adapted to the patient population. Results should not be interpreted using unvalidated thresholds copied from another device or institution. A normal or near-normal tracing does not exclude surgical bleeding, platelet dysfunction not detected by the selected assay, von Willebrand disease, or clinically important anticoagulant exposure. Conversely, abnormal results should not automatically trigger procoagulant therapy without assessment of thrombosis risk and bleeding source.

Clinical Relevance, Outcomes, Benefits, and Risks

The principal clinical benefit of viscoelastic testing is mechanistic precision during a rapidly changing event. It can identify the dominant functional defect, shorten the interval to treatment, reduce empiric transfusion, and provide an objective method for monitoring response. In cardiac surgery and trauma, algorithm-based use has frequently been associated with lower exposure to allogeneic blood products and fewer unnecessary interventions. Evidence for mortality, organ failure, and length-of-stay benefits is less consistent because studies differ in patient selection, protocol design, transfusion thresholds, and implementation quality.

Risks include false reassurance, overinterpretation of device-specific values, treatment of laboratory abnormalities that are not clinically relevant, and excessive administration of fibrinogen concentrates, plasma, platelets, or procoagulant factors. Thromboembolic events are a particular concern in patients with cancer, liver disease, pregnancy-related disorders, or mechanical circulatory support. Cost, maintenance, operator training, and interruptions in cartridge supply may also limit access. The safest approach combines validated testing with clinical examination, source control, standard laboratory monitoring, and multidisciplinary communication.

Expert Insights and Future Scope

Experts increasingly regard viscoelastic testing as a component of a broader hemostatic management system rather than a standalone diagnostic device. Its impact depends on the entire care pathway: early recognition, appropriate sampling, rapid reporting, treatment algorithms, bedside expertise, and reassessment. Hospitals should audit transfusion use, time to result, adherence to protocols, adverse events, and patient-centered outcomes. Future research should prioritize adequately powered randomized trials, standardized outcome definitions, evaluation of diverse bleeding populations, and cost-effectiveness analyses.

Further progress will likely involve multimodal testing that combines whole-blood clot dynamics with drug-specific assays, endothelial biomarkers, platelet function measurements, and genomic or proteomic information. The long-term objective is a responsive system that identifies the dominant biological defect without delaying definitive hemorrhage control. Such precision may reduce both under-treatment of coagulopathy and harmful overcorrection.

Conclusion

Viscoelastic testing offers a rapid, functional, and dynamic assessment of hemostasis in patients with complex critical bleeding. By evaluating clot initiation, strength, fibrin contribution, platelet effects, and fibrinolysis in whole blood, it can support mechanism-based transfusion and improve coordination of resuscitation. Its value is greatest when embedded in validated, multidisciplinary protocols that include early source control, physiological correction, repeated testing, and careful clinical interpretation. The technology has demonstrated important transfusion-management benefits in several high-risk settings, although effects on survival and major organ outcomes remain heterogeneous. Appropriate implementation, ongoing education, quality assurance, and prospective research are required to ensure that viscoelastic testing improves care without increasing thrombotic or transfusion-related harm.